Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

11.28
-0.0714-0.63%
Volume:2.81M
Turnover:31.11M
Market Cap:3.65B
PE:-20.67
High:11.30
Open:11.10
Low:10.83
Close:11.35
52wk High:12.58
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.82
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.08
PE(LYR):-23.01

Loading ...

Movement Alert|AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering

Market Focus
·
Aug 29

U.S. Small Caps Finish Mixed as AbCellera Biologics Leads, Bath & Body Works Lags

Dow Jones
·
Aug 26

AbCellera rises 17.0%

TIPRANKS
·
Aug 26

Major Insider Move Signals Growing Confidence in AbCellera Biologics

TIPRANKS
·
Aug 25

Abcellera Director Michael R. Hayden Reports $570,442 Common Share Purchase

Reuters
·
Aug 25

AbCellera Biologics call volume above normal and directionally bullish

TIPRANKS
·
Aug 20

Insider Confidence Surge: Director Makes Bold Move on AbCellera Biologics

TIPRANKS
·
Aug 19

Abcellera Director John S. Montalbano Acquires Common Shares Worth $110,300

Reuters
·
Aug 19

AbCellera Biologics (ABCL) Gets a Buy from BMO Capital

TIPRANKS
·
Aug 18

Abcellera Director Michael R Hayden Reports Purchase of Common Shares Worth $481,234.19

Reuters
·
Aug 14

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

AbCellera Dips After $200 Mln Share Sale for Menopause Drug

Reuters
·
Aug 13

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares

Reuters
·
Aug 13

AbCellera Prices Oversubscribed Public Offering at USD 9.75 Per Share to Raise USD 200 Million

Reuters
·
Aug 13

Abcellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

THOMSON REUTERS
·
Aug 13

Abcellera Biologics Inc.: Pricing of Public Offering of 17,435,897 Shares at a Price of $9.75 Per Share

THOMSON REUTERS
·
Aug 13

Shares of Abcellera Biologics Down 7.9% Premarket After Launching $200 Mln Stock Offering

THOMSON REUTERS
·
Aug 12

AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story

Simply Wall St.
·
Aug 12

AbCellera Biologics Launches $200 Million Public Offering

MT Newswires Live
·
Aug 12

Canada's Eupraxia Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 12